Resumen
To define the safety, tolerance, and selected renal and non-renal outcome measures in 73 SLE patients who received sirolimus therapy for more than 3 months in our institution over the past 21 years. In 12 patients who had lupus nephritis, proteinuria (p = 0.0287), hematuria (p = 0.0232), anti-DNA antibody levels (p = 0.0028) and steroid use were reduced (p = 0.0200). In the non-renal cohort of 61 patients, anti-DNA antibody levels (p = 0.0332) and steroid use were reduced (p = 0.0163). Both in the renal and non-renal cohorts, C3 (renal p = 0.0070; non-renal p = 0.0021) and C4 complement levels were increased (renal p = 0.0063; non-renal p = 0.0042) Adverse effects of mouth sores (2/73), headaches (1/73), and gastrointestinal discomfort were noted in a minority of patients (6/73). Sirolimus was only discontinued in two of 73 patients due to headache and recurrent infections, respectively. This study suggests that sirolimus is well tolerated and exerts long-term therapeutic efficacy in controlling renal and non-renal manifestations of SLE.
| Idioma original | English |
|---|---|
| Número de artículo | 108781 |
| Publicación | Clinical Immunology |
| Volumen | 229 |
| DOI | |
| Estado | Published - ago 2021 |
Nota bibliográfica
Publisher Copyright:© 2021 Elsevier Inc.
Financiación
This work was supported in part by grants AI072648 and AI141304 from the National Institutes of Health and the Central New York Community Foundation .
| Financiadores |
|---|
| National Institutes of Health (NIH) |
| Central New York Community Foundation |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Huella
Profundice en los temas de investigación de 'Improvement of renal and non-renal SLE outcome measures on sirolimus therapy – A 21-year follow-up study of 73 patients'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver